GEHC 10-Q Quarterly Reports

GE HealthCare Technologies Inc. reported solid revenue growth in the second quarter of 2026, with total revenues increasing by 5.7% year-over-year to $5.3 billion, driven by strong performance in its Advanced Imaging Solutions (AIS) and Pharmaceutical Diagnostics (PDx) segments. The company also benefited from the acquisition of Intelerad, which was integrated into the AIS segment. Net income attributable to GE HealthCare increased by 15.5% to $561 million, reflecting improved operational efficiencies and the positive impact of tariff refunds. Despite global macroeconomic uncertainties and supply chain challenges, GE HealthCare demonstrated resilience. The company successfully navigated the impact of tariffs through strategic pricing and the benefit of tariff refunds, which significantly boosted gross profit. However, the Patient Care Solutions (PCS) segment experienced a decline in revenue due to operational and fulfillment challenges. Looking ahead, the company remains focused on driving innovation and integrating strategic acquisitions while managing inflationary pressures and geopolitical risks.

GE HealthCare Technologies Inc. reported a decrease in net income attributable to GE HealthCare for the first quarter of 2026, down to $389 million from $564 million in the prior year period, primarily impacted by a significant increase in cost of products and services, alongside increased operating expenses. Total revenues saw a 7.4% increase to $5.13 billion, driven by growth in the PDx, Imaging, and AVS segments, with organic revenue growing 2.9%. The company completed a significant acquisition of Intelerad for approximately $2.3 billion, which contributed to a substantial increase in cash used for investing activities and a rise in goodwill. The company's operating income declined by 18.2% to $515 million, and the operating margin compressed by 310 basis points. This compression was largely attributed to higher cost of goods sold, impacted by cost inflation and incremental tariffs, as well as increased selling, general, and administrative expenses related to acquisitions. Despite these pressures, the company generated $290 million in cash from operating activities and $112 million in free cash flow, though this was impacted by the significant acquisition spend. The company also announced a strategic reorganization of its segments, combining Imaging and AVS into a new Advanced Imaging Solutions (AIS) segment starting in the second quarter of 2026.

GE HealthCare Technologies Inc. reported a solid third quarter of 2025, demonstrating revenue growth and a significant increase in net income compared to the same period last year. Total revenues grew by 6% year-over-year, driven by robust performance across most segments, particularly Pharmaceutical Diagnostics (PDx) which saw a notable 20% increase fueled by the acquisition of Nihon Medi-Physics (NMP) and organic growth. The company also experienced strong growth in the Imaging and Advanced Visualization Solutions (AVS) segments. Despite some headwinds in the Patient Care Solutions (PCS) segment, the overall revenue trajectory is positive, indicating continued demand for GE HealthCare's diverse product and service offerings. Profitability saw a substantial improvement, with Net Income Attributable to GE HealthCare increasing by 18% for the nine-month period and by 3% for the quarter. While operating income saw a slight decrease for the quarter due to increased cost of goods sold and services impacted by inflation and tariffs, the nine-month operating income showed a healthy increase. The company's strategic focus on acquisitions, such as NMP, and ongoing investments in R&D and commercial teams, position it well for future growth. GE HealthCare's strong cash flow generation and healthy balance sheet, including increased cash reserves and managed debt levels, further underscore its financial stability.

GE HealthCare Technologies Inc. reported solid financial results for the six months ended June 30, 2025, with total revenues increasing by 3% to $9.78 billion. Net income attributable to GE HealthCare saw a significant jump of 31% to $1.05 billion, or $2.29 per diluted share. This growth was driven by robust performance across its segments, particularly the Pharmaceutical Diagnostics (PDx) segment, boosted by the full acquisition of Nihon Medi-Physics Co., Ltd. (NMP). The company also demonstrated improved operational efficiency, with operating income rising 12% year-over-year. While gross profit faced some pressure from cost inflation and tariffs, this was partially offset by a decrease in operating expenses, including lower R&D and SG&A costs. The company's liquidity remains strong, with $3.76 billion in cash, cash equivalents, and restricted cash, and access to $3.5 billion in revolving credit facilities, positioning it well to meet its financial obligations and invest in future growth.

GE HealthCare Technologies Inc. (GEHC) reported a solid first quarter for 2025, with total revenues reaching $4.78 billion, a 3% increase year-over-year, and 4% on an organic basis. The company demonstrated strong profitability, with net income attributable to GE HealthCare rising 51% to $564 million, and diluted Earnings Per Share (EPS) increasing to $1.23 from $0.81 in the prior year. Key drivers of this performance include robust growth in the Pharmaceutical Diagnostics (PDx) segment and strong performance in the United States and Canada (USCAN). The company also benefited from a significant one-time gain from the remeasurement of its previously held 50% interest in Nihon Medi-Physics (NMP) as part of its acquisition. Despite some headwinds from unfavorable foreign currency impacts and ongoing challenges in the China market, GE HealthCare's operational execution and strategic acquisitions, like the full acquisition of NMP, are contributing positively to its financial results.

GE HealthCare Technologies Inc. (GEHC) reported a solid third quarter for 2024, with total revenues reaching $4.86 billion, a 1% increase both on a reported and organic basis compared to the prior year. This growth was driven by a 2% increase in service revenues and a slight uptick in product sales, despite challenges in the China market due to an ongoing anti-corruption campaign and delayed stimulus program. Operating income saw a significant increase of 10% to $676 million, and net income attributable to GE HealthCare common stockholders rose by 25% to $470 million, reflecting strong cost productivity and favorable pricing. The company also demonstrated robust cash flow generation, with operating cash flow of $1.04 billion for the nine-month period. Financially, GEHC maintained a strong balance sheet with $3.57 billion in cash, cash equivalents, and restricted cash as of September 30, 2024. The company successfully issued $1 billion in senior unsecured notes, strengthening its liquidity position. Remaining Performance Obligations (RPO) stood at $14.56 billion, indicating a healthy future revenue pipeline, though slightly down 1% from the end of 2023. The company's strategic acquisitions, such as MIM Software, are being integrated, and management remains optimistic about long-term growth prospects, particularly in expanding healthcare access globally.

GE HealthCare Technologies Inc. (GEHC) reported relatively flat total revenues of $4.84 billion for the three months ended June 30, 2024, a slight increase of 1% organically, compared to the prior year period. For the six-month period, total revenues remained flat at $9.49 billion. While product sales saw a slight decline, service revenues experienced growth, driven by pricing increases. Profitability showed a positive trend, with operating income increasing by 7% to $608 million for the quarter and by 2% to $1.15 billion for the six months. Net income attributable to GE HealthCare also saw an increase, reaching $428 million for the quarter and $802 million for the six months. The company reported strong performance in its Pharmaceutical Diagnostics (PDx) segment, which grew 12% in the quarter and 10% year-to-date, driven by volume, price, and new product introductions. Conversely, the China market continues to be a headwind, with revenues down 18% for the quarter, impacted by an ongoing anti-corruption campaign and delayed stimulus programs. Geographically, the United States and Canada (USCAN) region showed robust growth of 5% in the quarter, while EMEA was flat and the Rest of World grew 8%. The company has also made progress in its strategic acquisitions, including the acquisition of MIM Software Inc. in April 2024, which is expected to contribute to the Imaging segment. Cash flow from operations was $300 million for the six months, lower than the previous year, leading to a decrease in free cash flow, which management attributes to factors such as higher inventory levels and increased compensation and benefit payments.

GE HealthCare Technologies Inc. reported total revenues of $4.65 billion for the first quarter of 2024, a slight decrease of 1% compared to the prior year period, which was largely flat on an organic basis. This modest top-line performance was driven by mixed segment results, with the Pharmaceutical Diagnostics (PDx) segment showing strong growth, while Imaging, Ultrasound, and Patient Care Solutions (PCS) experienced declines. Despite the slight revenue dip, the company demonstrated improved profitability metrics. Operating income saw a slight decrease, but Adjusted EBIT and Adjusted Net Income increased by 3% and 6% respectively, indicating effective cost management and operational efficiencies. Diluted Earnings Per Share (EPS) significantly improved to $0.81 from $0.41 in the prior year, largely due to the absence of a large deemed preferred stock dividend related to redeemable noncontrolling interests in the prior year. The company maintained a strong liquidity position with $2.56 billion in cash and cash equivalents and access to substantial credit facilities, positioning it to fund operations and strategic initiatives, including a recent acquisition in April 2024.

GE HealthCare Technologies Inc. (GEHC) reported a 5% increase in total revenues for the third quarter of 2023, reaching $4.82 billion, and a 7% increase for the first nine months, totaling $14.35 billion. This growth was driven by strong performance across most segments, particularly Pharmaceutical Diagnostics (PDx) and Patient Care Solutions (PCS), with notable contributions from supply chain improvements and price increases. Despite revenue growth, net income attributable to GE HealthCare declined by 23% for the quarter and 14% year-to-date, primarily due to a significant increase in interest and other financial charges stemming from new debt issuances and the Term Loan Facility. The company also saw increased operating expenses related to its transition to a standalone entity and planned investments in R&D. Financially, GEHC ended the quarter with $2.42 billion in cash and cash equivalents. The company's long-term borrowings increased to $10.25 billion. While operating income remained stable year-over-year for the nine-month period, the significant increase in interest expenses impacted profitability. The company's guidance and outlook suggest continued revenue growth, but investors should monitor the impact of rising interest costs on net income and the company's ongoing investments in innovation and operational efficiency.

GE HealthCare Technologies Inc. reported solid top-line growth in its second quarter of 2023, with total revenues increasing by 7% year-over-year to $4.8 billion, and 9% on an organic basis. This growth was driven by strong performance across all segments, particularly Pharmaceutical Diagnostics (PDx) and Imaging. The company also saw continued improvements in supply chain fulfillment and benefits from price increases. Despite revenue growth, net income attributable to GE HealthCare decreased by 14% to $418 million, primarily impacted by higher interest expenses related to new debt issuances and the drawn Term Loan Facility, as well as increased operating expenses related to the company's transition to a standalone entity. The company also highlighted ongoing investments in R&D and commercial initiatives. GE HealthCare maintained a strong balance sheet with $1.9 billion in cash and cash equivalents and access to significant credit facilities, indicating financial stability. The company reiterated its full-year outlook, underscoring its confidence in continued growth and operational execution.

GE HealthCare Technologies Inc. (GEHC) reported its first quarterly results as an independent public company following its spin-off from General Electric in January 2023. For the first quarter of 2023, the company demonstrated solid revenue growth, with total revenues increasing by 8% to $4.7 billion, or 12% on an organic basis, driven by strong performance across all its reporting segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Despite the revenue growth, net income attributable to GE HealthCare saw a slight decrease of 4% to $372 million compared to the prior year. This was primarily due to increased interest expenses from new debt issuance and higher non-operating benefit costs related to pension plans transferred during the spin-off. The company also completed a strategic acquisition of Caption Health for $127 million, bolstering its AI-guided ultrasound capabilities. GEHC maintained a strong liquidity position with $2.3 billion in cash and cash equivalents and access to $3.5 billion in revolving credit facilities.